- Earlier this month, Freeline Therapeutics Holdings PLC (NASDAQ: FRLN) reported 2Q22 earnings focusing on the pipeline’s progress.
- Notably, the company said it is evaluating strategic options for FLT180a for hemophilia B and is reviewing how to streamline operations, including but not limited to seeking a partner to enable the continuation of FLT180a through Phase 3 development.
- Till the details on this potential pact are available, HC Wainwright is removing FLT180a from the model resulting in a price target of $15 from $20.
- The company expects an update from the Phase 1/2 trial (MARVEL-1) evaluating FLT190 in Fabry disease in 2H22.
- Dosing in the Phase 1/2 trial (GALILEO-1) evaluating FLT201 in Gaucher disease is expected to commence in 2H22, with initial data expected in 1H23.
- HC Wainwright writes, “we look forward to continued progress on the lead programs to drive robust shareholder value over the next year.”
- Price Action: FRLN shares are down 3.16% at $0.92 on the last check Monday.
HC Wainwright Cuts Price For This Small Cap ‘Reflecting Potential Pause In Hemophilia Program’
Earlier this month, Freeline Therapeutics Holdings PLC (NASDAQ: FRLN) reported 2Q22 earnings focusing on the pipeline’s progress. Notably, the company said it…
